Rep. Julie Johnson Sells Off Shares of Bio-Techne Co. (NASDAQ:TECH)

Posted by Wayne Rhoads on May 18th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on April 1st. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/30/2025.
Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 4/22/2025.
Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/22/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/15/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/11/2025.
Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 4/11/2025.
Sold $1,001 – $15,000 in shares of DT Midstream (NYSE:DTM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Carlisle Companies (NYSE:CSL) on 4/7/2025.

Bio-Techne Stock Up 1.9%

Shares of NASDAQ TECH opened at $49.15 on Friday. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a 52 week low of $46.01 and a 52 week high of $84.22. The firm has a 50-day moving average price of $53.46 and a 200 day moving average price of $65.50. The stock has a market capitalization of $7.71 billion, a price-to-earnings ratio of 49.65, a price-to-earnings-growth ratio of 2.88 and a beta of 1.46.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. The firm had revenue of $316.18 million during the quarter, compared to analysts’ expectations of $317.92 million. Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.48 earnings per share. Equities research analysts anticipate that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne announced that its Board of Directors has approved a stock buyback plan on Wednesday, May 7th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 6.5% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Bio-Techne Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 30th. Investors of record on Monday, May 19th will be paid a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Monday, May 19th. Bio-Techne’s dividend payout ratio (DPR) is 39.02%.

Wall Street Analyst Weigh In

TECH has been the subject of a number of research reports. Stifel Nicolaus cut their target price on shares of Bio-Techne from $75.00 to $60.00 and set a “hold” rating for the company in a research report on Thursday, May 8th. Robert W. Baird cut shares of Bio-Techne from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Friday. KeyCorp restated a “sector weight” rating on shares of Bio-Techne in a research report on Wednesday, April 9th. Finally, Royal Bank of Canada cut their target price on shares of Bio-Techne from $72.00 to $63.00 and set a “sector perform” rating for the company in a research report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Bio-Techne has a consensus rating of “Hold” and an average price target of $73.44.

View Our Latest Research Report on TECH

Institutional Investors Weigh In On Bio-Techne

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Bio-Techne by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 18,594,608 shares of the biotechnology company’s stock valued at $1,339,370,000 after purchasing an additional 275,644 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Bio-Techne by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company’s stock valued at $666,933,000 after purchasing an additional 721,012 shares during the period. Select Equity Group L.P. grew its holdings in Bio-Techne by 129.8% in the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company’s stock valued at $314,609,000 after purchasing an additional 3,030,644 shares during the period. Ameriprise Financial Inc. grew its holdings in Bio-Techne by 7.2% in the fourth quarter. Ameriprise Financial Inc. now owns 4,702,942 shares of the biotechnology company’s stock valued at $338,756,000 after purchasing an additional 317,349 shares during the period. Finally, Invesco Ltd. grew its holdings in Bio-Techne by 9.7% in the first quarter. Invesco Ltd. now owns 4,190,115 shares of the biotechnology company’s stock valued at $245,666,000 after purchasing an additional 369,651 shares during the period. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Bio-Techne Company Profile

(Get Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.